Expression Of Macrophage Migration Inhibitory Factor Is Associated With Gynecologic Malignant Tumor

The correlation between macrophage migration inhibitory factor and gynecologic tumorObjective: Macrophage migration inhibitory factor (MIF) was reported to inactivate p53 and play an essential role in the cell proliferation, growth and angiogenesis of tumors. However, the potential roles of MIF in regulating gynecologic carcinoma have not been studied yet. In our study, the expressions of MIF in the serum and ascitic fluids of gynecologic tumor patients were observed to determine whether the correlated between MIF and gynecologic malignant tumors.Method: A total of 46 women suffering from gynecologic malignant tumor, from January to November 2005, and 24 controls of benign neoplasm were included in this study. The MIF level of serum and ascitic fluids was measured using ELISA, both VEGF and CA125 concentration of patients'blood was detected contemporarily.Results: The MIF levels in abdominal fluid of patients with gynecologic cancer were significantly higher than those of the controls (P=0.004). But there is no difference between the two groups in serum MIF level (P=0.061). Both ascites and serum MIF level of ovarian cancer markedly differed from those of patients with benign ovarian tumor (P=0.0001, P=0.0095). And a comparison of ascites MIF level and serum CA125 values in ovarian cancer patients showed a positive correlation (correlation coefficient r=0.6649, P=0.0256). A positive correlation was also found between the ascites concentration of MIF in patients with malignant carcinoma and the serum VEGF leve(lr=0.405,P=0.0325).The difference of ascites , serum MIF level in cases with uterine malignant tumor including cervical cancer and endometrial carcinoma and those of patients with myoma were not significant(P=0.7820,P=0.2447).